Jacobio Pharmaceuticals Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jacobio Pharmaceuticals Co. sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Jacobio Pharmaceuticals Co.: 7 sponsored US clinical trials, 3 recruiting.
Jacobio Pharmaceuticals Co. sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 2 trials.
Upper-quartile sponsor footprint
Jacobio Pharmaceuticals Co. sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
NCT06973564
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT05002270
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
NCT04587479
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
NCT04045496
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
NCT03518554
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
What is open in the Jacobio Pharmaceuticals Co. pipeline
3 recruiting of 7 indexed (43% open); 4 completed (57%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Solid Tumors (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jacobio Pharmaceuticals Co.: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
Jacobio Pharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this Jacobio Pharmaceuticals Co. page
7 registered trials is a research-attention snapshot, not an endorsement of Jacobio Pharmaceuticals Co. or any single study.
- 3 of Jacobio Pharmaceuticals Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Solid Tumors is the condition Jacobio Pharmaceuticals Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Jacobio Pharmaceuticals Co. pipeline card: 7 registered trials from official public datasets.Report a data error.